**Supplementary Table 1 Main characteristics of studies on the Arg264Cys polymorphism and prostate cancer**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| First author(year) | Country | Ethnicity | Study design | Source of control | Sample size | AgeCase/control | Sampleacquisition | Genotypingmethod | HWE | NOS |
| total cases | Unselected cases | Familial cases | control |  |  |  |  |  |
| Modugno (2001) | America | Caucasian | Case-control | PB | 88 | NA | NA | 241 | 68.9/73.6 | Peripheral blood | PCR-RFLP | 1.00 | 6 |
| Suzuki(2003) | Japan | Asian | Case-control | HB | 101 | 0 | 101 | 114 | 69.8/71.2 | Peripheral blood | PCR-SSCP | 0.14 | 6 |
| Fukatsu(2004) | Japan | Asian | Case-control | HB  | 107 | NA | NA | 187 | 71.3±8.3/70.4±7.5 | Peripheral blood in all cases; Peripheral blood or frozen prostate tissue in controls | PCR-RFLP | 0.19 | 5 |
| Sarma(2008) | America | African-American | Case-control | PB | 131 | 103 | 28 | 341 | 67.2±8.6/62.1±10.1 | Peripheral blood | High-throughput genotyping | 0.45 | 6 |
| Onsory(2008) | India | Indian | Case-control | HB | 100 | NA | NA | 100 | NA | Peripheral blood or frozen prostate tissue | PCR-RFLP | <0.01 | 7 |
| Travis(2009) | AmericaEurope | mixed | Nested case-control | PB | 8919 | NA | NA | 8038 | 68/68 | Peripheral blood | TaqMan | <0.01 | 7 |
| Holt(2013) | America | Caucasian | Case-control | PB | 1272 | NA | NA | 1247 | 35-74/35-74 | Peripheral blood | SNPlexTM Genotyping System | 1.00 | 7 |
| Kachakova(2016) | Bulgaria | Caucasian | Case-control | HB &PB | 241 | NA | NA | 261 | 69.25/NA | Peripheral blood | PCR-RFLP PCR-SSCP | 0.31 | 6 |
| Price#(2016) | America | Caucasian | Nested case-control | PB | 865 | NA | NA | 839 | 63.96/63.74 | Peripheral blood | TaqMan | 1.00 | 6 |

*PB* population based, *HB* hospital based, *HWE* Hardy-Weinberg equilibrium, *PCR* polymerase chain reaction, *RFLP* restriction-fragment length polymorphism, *SSCP* single-strand conformation polymorphism, *BPH* benign prostate hyperplasia, *NA* not available, *NOS* the Newcastle-Ottawa Scale.

#A nested case-control study, in which the intervention measures might have influenced the risk of prostate cancer; only the placebo arm data were used.